Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

Abstract

Endothelial dysfunction is an independent predictor for cardiovascular events in patients with type 2 diabetes ( T2DM ). Glucagon like peptide‐1 ( GLP ‐1) reportedly exerts vasodilatory actions, and inhibitors of dipeptidyl peptidase‐4 ( DPP ‐4), an enzyme‐degrading GLP ‐1, are widely used to treat T2DM . We therefore hypothesized that DPP ‐4 inhibitors ( DPP ‐4Is) improve endothelial function in T2DM patients and performed 2 prospective, randomized crossover trials to compare the DPP ‐4I sitagliptin and an α‐glucosidase inhibitor, voglibose (in study 1) and the DPP ‐4Is sitagliptin and alogliptin (in study 2). In study 1, 24 men with T2DM (46±5 years) were randomized to sitagliptin or voglibose for 6 weeks without washout periods. Surprisingly, sitagliptin significantly reduced flow‐mediated vasodilatation ( FMD ; −51% compared with baseline, P P P <0.001, before/after alogliptin, respectively). Interestingly, FMD reduction was less evident in subjects who were on statins or whose LDL cholesterol levels were reduced by them, but this was not correlated with parameters including DPP ‐4 activity and GLP ‐1 levels or diabetic parameters. Our 2 independent trials demonstrated that DPP ‐4 inhibition attenuated endothelial function as evaluated by FMD in T2DM patients. This unexpected unfavorable effect may be a class effect of DPP ‐4Is. URL: http://center.umin.ac.jp , Unique Identifiers: UMIN000005682 (sitagliptin versus voglibose) and UMIN000005681 (sitagliptin versus alogliptin).